



## resTORbio to Present at the Canaccord Genuity 38th Annual Growth Conference

July 30, 2018

BOSTON, July 30, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that company management will present a corporate overview at the Canaccord Genuity 38<sup>th</sup> Annual Growth Conference on Thursday, August 9, 2018 at 3:00 p.m. ET in Boston, MA.

A live audio webcast of the presentation can be accessed on the Investors section of resTORbio's website at <http://ir.restorbio.com/investors>. An archived replay will be available for at least 30 days following the presentation.

### About resTORbio

resTORbio, Inc. is a clinical stage biopharmaceutical company targeting TORC1 and other biological pathways that regulate aging to develop innovative medicines with the potential to extend healthy lifespan. resTORbio's lead program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular and central nervous systems.

### Investor Contact:

Jennifer Robinson  
resTORbio, Inc.  
857-772-7029  
[jrobinson@restorbio.com](mailto:jrobinson@restorbio.com)

### Media Contact:

Courtney Heath  
Scient PR  
617-872-2462  
[courtney@scientpr.com](mailto:courtney@scientpr.com)

 [Primary Logo](#)